KR101141314B1 - Composition for immunopotentiating comprising the extract of herbal formula, Ojeok-san - Google Patents

Abstract

The present invention relates to a composition for enhancing immunity, comprising a potic acid extract as an active ingredient, a food composition for enhancing immunity, and a composition for preventing or treating diseases caused by a decrease in immune function.

Description

Composition for immunopotentiation comprising Ojeoksan extract as an active ingredient {Composition for immunopotentiating comprising the extract of herbal formula, Ojeok-san}

The present invention relates to a composition for enhancing immunity, comprising a potic acid extract as an active ingredient, a food composition for enhancing immunity, and a composition for preventing or treating diseases caused by a decrease in immune function.

Ojeoksan was first published in the Taepyeong Hyeminje National Defense Sanhan Gate, first revised and published by Jinsamun around 1107. Dermis, Tak-bak, Gil-gyeong, Crust, Dang-gu, Health, Baek-jak-pyeon, Baek-bok-ryeong, Cheong-gung It consists of white paper, white, half cinnamon, cinnamon, licorice, ginger and baekbaek. It is a prescription that is adapted to the use of 身 사, intrathoracic abdominal pain (四 상 作 統) or normal cold regeneration (식 生 食). In Korea, 56 traditional Chinese herbal medicine prescriptions have been paid by national insurance since 1990. Of these 56 Chinese medicine prescriptions, Oeroksan ranks first in terms of number of medication days or drug costs. In 2008 health insurance, Oh Jeung-san among 56 national health insurance-beneficial herbal medicines was found to be an important prescription for Chinese medicine, which takes up 19% of the days of medication and 33% of medical expenses. National Health Insurance Corporation, 2008 National Health Insurance Statistical Yearbook, 2008 P.290).

It is published about the efficacy of Ojeok-san, which is known for its safety against liver and kidney toxicity, anti-inflammatory, analgesic, antipyretic, hyperlipidemia, and treatment of menopausal anxiety disorders. It has not been done.

In this regard, the present inventors studied the efficacy related to the immunological activity against the formulation of Ohjeksan prescription. To this end, macrophage activation effects (Friedl R, Moeslinger T, Kopp B, and Spieckermann PG.Stimulation of nitric oxide synthesis by the aqueous extract of Panax ginsena root in Raw 264.7 cells.British Journal of pharmacology, 2001; 134: 1663-1670) and the proliferation effect of splenocytes.

In particular, the NO production promoting effect is an indicator of macrophage activation. NO produced in macrophages is known to play a role in eliminating invading pathogens and acting as a basic host defense system (Farrell AJ, Blake DR. Nitric oxide. of the Rheumatic Dieases. 1996; 55: 7-20). In particular, when Thhl is divided into Thl and Th2 in the ThO differentiation stage, it is known to have a function of helping to differentiate to Th1. In addition, cytotoxic activity of killing cancer cells, parasites or bacteria among leukocyte activity has been reported to be released by the release of NO (Nathan C. Nitric oxide as a secretory product of mammalian cells.FASEB Journal. 1992; 6: 3051-3064) ). In addition, NO is immunomodulating between T-cell and endothelial cells (Bingisser RM, Holt PG Immunomodulating mechanism in the lower respiratory tract; nitric oxide mediated intraction between alveolar macrophage, epithelial cell, and T-cell, SWISS Medical Weekly. 2001; 131; 171-179) is known to have a potent platelet aggregation inhibitory effect.

In this regard, the present inventors suggest that the formulation of Ojeoksan prescription extract promotes the proliferation of splenocytes, induces the production of NO in macrophages, and shows an excellent effect on the enhancement of immune sensitization in mice. By confirming that the present invention was completed.

The present invention is to provide a composition for the enhancement of immunity, a composition for enhancing immunity, and a composition for the prevention or treatment of diseases caused by a decrease in immune function.

In order to solve the above problems, the present invention provides a composition for enhancing immunity containing a prescription formulation of Ohpisan as an active ingredient.

The term "ojeoksan" used in the present invention, Atractylodis Rhizoma, Ephedrae Herba, Dermis, Citri Unshii Pericarpium, Magnoliae Cortex, Gilkyung , Platycodi Radix, Aurantii Fructus Immaturus, Angelicae Gigantis Radix, Health (Zingiberis Rhizoma), Paeoniae Radix, Paekoniae Radix, Hoelen, White Paper ( White, Angelicae Dahuricae Radix, Cnidii Rhizoma, Pinelliae Tuber, Cinnamon Bark, Glycyrrhizae Radix et Rhizoma, Ginger (Zingiberis Rhizoma Crudus) And Allii Radix. The composition is according to "consensus" and has not been reported for the efficacy associated with the immunological activity of miscalculated acid.

As used herein, the term "extract" means a specific component that is separated from a miscalculated acid using a solvent of the liquid. As the solvent, water, C ₁ to C ₄ alcohol or a mixed solvent thereof may be used. In order to efficiently extract the active ingredient, it is preferable to extract with methanol, ethanol or a mixture of these and water. The concentration of methanol and ethanol is preferably 10 to 90%, more preferably 50 to 70%, but is not limited thereto. The extraction solvent is preferably used 5 to 20 times the weight of the cumulative acid.

The extraction method may be any one selected from the group consisting of hot water extraction, cold extraction, reflux cooling extraction, ultrasonic extraction and steam extraction, the extract may be obtained by lyophilizing the extract after extraction. When water is used as the extraction solvent, hot water extraction is preferred, the temperature of the water is preferably 90 to 120 ℃, extraction time is 1 to 3 hours.

The present invention also provides a pharmaceutical composition for the prevention or treatment of diseases caused by a decrease in immune function containing the composition for enhancing immune function as an active ingredient.

The term "prevention" as used in the present invention means any action that inhibits or delays the disease by administration of the composition comprising the above-obtained acid extract. In addition, the term "treatment" as used in the present invention means all the actions that improve or cure the symptoms of the disease by administration of the composition comprising the acid cumulative extract.

As used herein, the term "immune-enhanced" means a function that promotes an immune response to an antigen in the process of initial activation of immune cells, or enhances immunity by increasing the activity of cells of the immune system.

In the present invention, the disease due to impaired immune function may be any one selected from the group consisting of colds, allergic diseases, chronic fatigue, and cancer. In addition, examples of the allergic disease include atopy, asthma, allergic rhinitis.

In a specific embodiment of the present invention, it was found that the nitric acid extract activates macrophages by confirming that the production of nitric oxide (NO) is increased by controlling the concentration when the ohmic acid extract is treated with macrophages (FIG. 1). ). In addition, it was confirmed through the spleen cell proliferation experiment that the erythroid extract induces the growth of splenocytes in a concentration-dependent manner (FIG. 2), and the IL-2 concentration in the culture medium was increased (FIG. 3). Furthermore, in vivo experiments, it was confirmed that the splenocytes were increased (Fig. 4), and the blood concentrations of IgG1 and IgM were increased when the OJ extract was administered to mice sensitized with OVA. (FIG. 5). Therefore, it can be seen that the ohjeok extract of the present invention has an excellent effect on enhancing the immune response.

The composition of the present invention may include a pharmaceutically acceptable carrier, excipient or diluent in addition to the above-described active ingredient for administration. The carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

The compositions of the present invention can be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral formulations, suppositories, or sterile injectable solutions, respectively, according to conventional methods. Specifically, when formulated, it may be prepared by using diluents or excipients such as fillers, weighting agents, binders, wetting agents, disintegrating agents, and surfactants which are commonly used. Solid preparations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, and the like. Such solid preparations may be prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, gelatin, and the like, with the oxalic acid extract. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. It may be prepared by adding various excipients such as humectants, sweeteners, fragrances, preservatives and the like in addition to liquid oral liquids or liquid paraffin for oral use. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like can be used. As the base of the suppository, utopsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The compositions of the present invention can be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or topically) according to the desired method, and the dosage is based on the condition and weight of the patient, the extent of the disease, Depending on the drug form, route of administration, and time, it may be appropriately selected by those skilled in the art. The daily dosage of the oxalic acid extract is preferably 1 mg / kg to 500 mg / kg, and may be administered once to several times daily if necessary.

In addition, the present invention provides a method for preventing or treating a disease due to impaired immune function, comprising administering to a subject a therapeutically effective amount of a composition containing the composition for enhancing immune function as an active ingredient.

The present invention also provides an immune enhancing food composition containing the immune enhancing composition as an active ingredient.

The food composition includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and salts thereof, organic acids , Protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. Others may contain pulp for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components can be used independently or in combination. In addition, the food composition is any one of meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, gum, ice cream, soups, drinks, tea, functional water, drinks, alcoholic beverages and vitamin complexes Can be.

In addition, the food composition may further include food additives, and the suitability as a "food additive" standards for the item according to the General Regulations of the Food Additives Code and General Test Law, etc., unless otherwise specified. And based on the criteria.

Examples of the items listed in the "Food Additives Code" include, for example, chemical synthetic products such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as navy, licorice extract, crystalline cellulose, high quenching pigment, and guar gum. And mixed preparations such as sodium L-glutamate, alkalescent additives, preservatives and tar dyes.

At this time, the extract according to the present invention is added to the food containing the beverage in the process of preparing the food composition, if necessary, can be appropriately added or subtracted, preferably 1 to 15% by weight in 100% by weight of food. It is preferable to add.

In addition, the present invention comprises the steps of preparing the extract by extracting the acid as an extract solvent; And it provides a method for producing an immune enhancing composition containing the Ohsiksan prescription extract comprising the step of drying the extract as an active ingredient.

As the extraction solvent, water, C ₁ to C ₄ alcohol or a mixed solvent thereof may be used. In order to efficiently extract the active ingredient, it is preferable to extract with methanol, ethanol or a mixture of these and water. The concentration of methanol and ethanol is preferably 10 to 90%, more preferably 50 to 70%, but is not limited thereto. The extraction solvent is preferably used 5 to 20 times the weight of the cumulative acid. In the case of the water extract is preferably hot water extraction is most preferably extracted for 1 to 3 hours at 90 ~ 120 ℃.

The extraction method may be any one selected from the group consisting of hot water extraction, cold extraction, reflux cooling extraction, ultrasonic extraction and steam extraction, the extract may be obtained by lyophilizing the extract after extraction.

Ojeoksan prescription extract of the present invention increases the growth of splenocytes of mice, increases the production of NO in macrophages, and is effective in enhancing immune function because it shows an excellent effect on immune enhancement in mice, thereby enhancing immune function. It is useful for use as a pharmaceutical composition for preventing or treating a disease caused by a composition for use, a food composition for enhancing immune function and a decrease in immune function.

FIG. 1 is a result of detecting the activity of macrophages of the Ojeok extract by measuring the amount of NO produced when macrophages are activated.
FIG. 2 shows the results of searching for proliferation-inducing effects of splenocytes as a result of immunological activity on splenocytes of the Ojic acid extract.
Figure 3, as a result of the immune activity search results for splenocytes of the Ohjeoksan extract, showing the results of measuring the IL-2 level in the culture by collecting the remaining cells after the proliferation effect of the splenocytes.
Figure 4 shows the in vivo immune activating effect of the extract of Ojeoksan extract, after administration of the drug to mice sensitized with OVA, splenocytes were isolated and splenocytes isolated from the respective administration groups as mitogen OVA, LPS and Con A were treated to show mitogen effect results.
5 shows the in vivo immune activation effect of the Ojeoksan extract, the results of measuring the blood OVA-specific IgG, OVA-specific IgG1, IgM levels after administration of the drug to mice sensitized with OVA antigen It is shown.

Hereinafter, preferred embodiments of the present invention will be presented to assist in understanding the present invention. However, the following examples are merely provided to more easily understand the present invention, and the contents of the present invention are not limited by the examples.

Example 1 Preparation of a Ohmic Acid Prescription Extract

For the composition of Ojeoksan, refer to 'Agreement' and create, Atractylodis Rhizoma, Ephedrae Herba, Citri Unshii Pericarpium, Magnoliae Cortex, Gilkyung , Platycodi Radix, Aurantii Fructus Immaturus, Angelicae Gigantis Radix, Health (Zingiberis Rhizoma), Paeoniae Radix, Paekoniae Radix, Hoelen, White Paper ( White, Angelicae Dahuricae Radix, Cnidii Rhizoma, Pinelliae Tuber, Cinnamon Bark, Glycyrrhizae Radix et Rhizoma, Ginger (Zingiberis Rhizoma Crudus) ), The mass ratio of medicinal herb (Allii Radix) is about 7.5: 3.75: 3.75: 3: 3: 3: 3: 3: 3: 3: 2.625: 2.625: 2.625: 2.625: 2.25: 3.75: 3.75 Used as.

Dermis, Gilgyeong, Dongguk, Health, Baekjak, Baekbokyeong, Baekji, Cheongung, and Ginger were purchased from Yeongcheon, Korea, and HMAX (Chungbuk, Korea) Cinnamon was purchased from Hwarim Pharmaceuticals and Chongbaek was purchased from local markets.

Each medicinal herb was mixed by ratio and extracted with hot water extractor (COSMOS-660, Gyeongseo Machinery Industry, Korea) for 100 to 120 minutes with 10 times the weight of medicinal herbs. After extracting the filtrate was concentrated first with a large rotary concentrator (EYELA N-11, Japan) and then using a freeze dryer (PVTFD100R, Ilshin Lab., Korea) to recover the yellowish brown extract powder. The yield of the ohmic acid extract powder was about 21.0%.

Experimental Example 1 Search for Immune Activity Against Macrophages

1) Cell Culture

Raw 264.7 cells, a Murin macrophage cell line, were distributed from ATCC (American Type Culture Collection, USA) and used. 10% Fetal Bovine Serum (FBS; Gibco BRL., Grand Island, NY, USA) as a culture medium, Penicillin-streptomycin mixture (Gibco BRL., Grand Island, NY, USA) as an antibiotic Dulbecco's modified Eagle Medium (DMEM; Gibco BRL., Grand Island, NY, USA) was used and incubated in an environment of 37 ° C., 5% CO ₂ . The culture medium was exchanged 2-3 times a week and the cells attached to the culture flasks were separated using a scraper and passaged once a week to keep the cells inactive.

2) Cytotoxicity Screening of Macrophages

In order to detect the effect of Ojeok extract on the cytotoxicity of macrophage lines, RAW 264.7 cells were divided into 3 × 10 ³ cells / well in 96-well plates, and medicinal extracts were dissolved in PBS and added to each concentration. After 2 days of incubation, the solution was added for 4 hours with a tetrazolium salt CCK-8 kit (Cell Counting Kit-8, Dojindo Laboratories, Tokyo, Japan) solution, and then incubated for 4 hours using an ELISA reader (Benchmark Plus, BIORAD, USA). Absorbance was measured at nm. The ratio of absorbance of drug addition wells to absorbance of control wells was calculated in% and the mean value of several wells was used. The calculation is as follows.

% = {(Average _450nm average value of drug well)-(Abs _450nm average value of blank well)} / {(Abs _450nm average value of control well)-(Abs _450nm average value of blank well)} × 100

3) Measurement of NOx Production

When macrophages are activated, NO is produced by activation of nitric oxide synthase (NOS), and the amount of NO production was measured as an indicator of macrophage activation. RAW 264.7 cells were divided into 48 wells at 2.5 × 10 ⁵ cells / well, stabilized by incubation in a CO ₂ incubator for 24 hours, and then treated with extracts. As a positive control, LPS was treated by concentration. After 18 hours of incubation, the supernatant was separated and NO production was measured. The amount of NO produced was calculated by measuring the absorbance at 535 nm using the Griess reagent and the concentration was calculated.

4) Results

The effect of NO production, one of the activation indices of RAW 264.7 (murin macrophage cell line) cells, was investigated. First, it was determined that the cytotoxicity was treated with 0, 2, 10, 20, 100, 200, 1000 μg / ml, and 200 μg / ml, which did not show cytotoxicity, was set to the highest concentration. The results of the NO production for the concentration of 12.5, 25, 50, 100, 200 μg / ml was searched and the results are shown in FIG. The results were expressed as mean ± SEM, and ANOVA and Bonferroni multiple comparison analysis were used. Significant differences between the normal and induced groups were #; p <0.05, ##; p <0.01, and when compared with the induction group and the drug treatment group *; p <0.05, **; p <0.01.

As shown in FIG. 1, the Ojic acid extract showed a concentration-dependent NO production effect at a concentration of 50 μg / ml or more (p <0.01), and a level similar to LPS 0.25 μg / ml used as a positive control at 200 μg / ml. NO production was increased.

Experimental Example 2 Screening of Immune Activity Against Splenocytes

1) Culture of Splenocytes

Six-week-old male ICR mice (Hallim experimental animals, Chungbuk-negative) were extracted after the cervical spine bone. The extracted spleens were washed with HBSS (Hank's Balanced Salt Solution, Gbico BRL.), Splenocytes were separated using a syringe, and red blood cells were removed with RBC lysing buffer (Sigma Chemical Co, MO, USA), followed by 10% FBS and penicillin. -Suspended in RPMI 1640 medium (Gbico BRL.) Containing streptomycin and incubated at 5% CO ₂ , 37 ℃.

2) Cell proliferation effect of splenocytes

To investigate the effect of medicinal extracts on splenocyte growth, splenocytes isolated and cultured in 96-well plates were divided into 5 × 10 ⁵ cells / well, and medicinal extracts were dissolved in PBS and added to each concentration. Con A and LPS were used as a comparative material for the cell proliferation effect of medicinal herbs. After 48 hours of incubation, the solution was added for 4 hours by adding a solution of tetrazolium salt (CK-8 kit (Cell Counting Kit-8, Dojindo Laboratories, Tokyo, Japan)), and then absorbance was measured at 450 nm using an ELISA reader. The ratio of absorbance of drug addition wells to absorbance of control wells was calculated in% and the average value of the various wells was used. The calculation is as follows.

% = {(Average _450nm average value of drug well)-(Abs _450nm average value of blank well)} / {(Abs _450nm average value of control well)-(Abs _450nm average value of blank well)} × 100

3) results

Mouse splenocytes were isolated and the results of searching for proliferation-inducing effects of splenocytes after drug treatment are shown in FIG. 2. The results were expressed as mean ± SEM, and ANOVA and Bonferroni multiple comparison analysis were used. Significant differences between the normal and induced groups were #; p <0.05, ##; p <0.01, and when compared with the induction group and the drug treatment group *; p <0.05, **; p <0.01.

As shown in FIG. 2, when 1 and 2 μg / ml of the T-cell mitogen Con A used as a positive control group, more than 300% of the control group induced cell proliferation (P <0.01), and 0.1 and 1.0 μg when treated with LPS. Cell growth was induced in a concentration-dependent manner at / ml (p <0.05, p <0.01, respectively). Ojeoksan extract showed a tendency to induce cell proliferation in a concentration-dependent manner, and proliferated at 50 and 100 μg / ml to 123.2% (p <0.05) and 136.8% (p <0.01) of the control, respectively, and 200 μg / ml At high concentrations of, it was again reduced.

In addition, the results of measuring the IL-2 level in the culture by collecting the cells remaining after the proliferation effect of the splenocytes are shown in FIG. As shown in FIG. 3, the treatment of the Ojic acid extract increased about 2.5 times more than the IL-2 concentration of the control group.

Experimental Example 3 Screening of Immune Activity for OVA Sensitized Animal Models

1) experimental animals and administration

Six-week-old male C57BL / 6 mice were sensitized by three intraperitoneal injections of 100 μg + 200 μg / 100 μl of Ovalbumine + aluminum (OVA + Al) as an antigen (Day 1, Day). 8 and Day 15). Drug samples were administered orally at 1 g / kg once a day for three weeks from Day 1, and the control group was administered with distilled water as an excipient. After 3 weeks of administration, the blood was collected and the IgG and IgM were quantified (ELISA method). After collecting blood, the spleen was extracted to separate splenocytes.

2) mitogen effect of splenocytes

Splenocytes were isolated from the spleens and the splenocytes were dispensed into 96 wells for each administration group, and then treated with control and splenocyte activating substances (Concanavalin A, LPS). Search using. The extra splenocytes of each dose group isolated RNA to detect changes in gene expression.

In order to evaluate the effects of immune activation in vivo, the drug was administered to mice sensitized with OVA antigen, and then splenocytes were isolated and treated with OVA, LPS and Con A as mitogen to splenocytes isolated from each administration group. The effect was confirmed, and the result is shown in FIG. The results were expressed as mean ± SEM, and ANOVA and Bonferroni multiple comparison analysis were used. Significant differences between the normal and induced groups were #; p <0.05, ##; p <0.01, and when compared with the induction group and the drug treatment group *; p <0.05, **; p <0.01.

As shown in Figure 4, when the control group (control) as a control to show the cell proliferation effect on this, in the OVA-sensitized group (OVA + Al), each group treated with OVA with mitogen 116.0 ± 4.9 % (P> 0.05), LPS-treated group was 150.6 ± 5.0% (P <0.01), ConA-treated group 153.6 ± 2.0% (P <0.01) was confirmed that the increase in cell proliferation by treatment with LPS or ConA. In addition, compared to the OVA + Al group in the group to which each drug was administered to the OVA sensitized mice, the OJ-treated group showed a significant proliferative effect on the OVA, LPS and ConA.

3) Quantification of IgG and IgM

The amount of IgG and IgM in the collected plasma was quantified by ELISA method using the respective measurement kit (Bethyl laboratories Inc., USA).

In order to evaluate the effect of immune activation in vivo, after administration of the drug to mice sensitized with OVA antigen, blood OVA-specific IgG, OVA-specific IgG1, IgM levels were measured, and the results are shown in FIG. The results were expressed as mean ± SEM, and ANOVA and Bonferroni multiple comparison analysis were used. Significant differences between the normal and induced groups were #; p <0.05, ##; p <0.01, and when compared with the induction group and the drug treatment group *; p <0.05, **; p <0.01.

As shown in FIG. 5, the concentration of OVA-specific IgG and OVA-specific IgG1 was increased due to sensitization of OVA + Al, and 3.3 and 3.4 times higher than that of the OVA + Al group, respectively. I could confirm it. In addition, the blood concentration of IgM was not different between the normal group and the OVA + Al sensitized group.

Hereinafter, the pharmaceutical examples of the pharmaceutical and food compositions are exemplified as follows, but for the purpose of illustrating the present invention only, it is not intended to limit the present invention.

Formulation Example 1 Preparation of Powder

According to the preparation method of powder in the pharmacopeia formulation, it was prepared in the following component content per one packet.

Ojeoksan Extract 400 mg

Lactose 100 mg

Talc 10 mg

The powders were prepared by mixing the ingredients and filling the final foam.

Formulation Example 2 Preparation of Tablet

According to the preparation method of the tablet in the pharmacopeia formulation, it was prepared in the following component content per tablet.

Ojeoksan Extract 400 mg

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, a tablet was prepared by a direct stroke method.

Formulation Example 3 Preparation of Capsule

According to the preparation method of the capsules in the pharmacopeia formulation, it was prepared in the following component content per capsule.

Ojeoksan Extract 400 mg

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After the powder was prepared by mixing the above components, the powder was filled in a hard capsule according to the conventional method for preparing a capsule to prepare a capsule.

Formulation Example 4 Preparation of Injection

According to the preparation method of injectables in the pharmacopeia formulation, it is prepared in the following component contents per ampule (2 ml).

Ojeoksan Extract 400 mg

Appropriate sterile distilled water for injection

pH adjuster

According to the conventional method for preparing an injection, the amount of the above ingredient was prepared per ampoule (2 ml).

Formulation Example 5 Preparation of Liquid

According to the method for preparing a liquid formulation in the Pharmacopoeia General Formulation, it is prepared in the following component content per 100 ml of the liquid formulation.

1 g of red pepper acid extract

10 g of isomerized sugar

5 g of mannitol

Purified water

Each component was added to and dissolved in purified water according to the usual liquid preparation method, and lemon flavor was added appropriately, followed by mixing the above components. Then, purified water was added thereto to adjust the total volume to 100 ml, and the solution was prepared by sterilization by filling in a brown bottle.

Formulation Example 6 Preparation of Health Food

1 g of red pepper acid extract

Vitamin mixture proper amount

70 μg of Vitamin A Acetate

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

Vitamin B2 0.15 mg

Vitamin B6 0.5 mg

0.2 μg of vitamin B12

Vitamin C 10 mg

10 μg biotin

Nicotinic Acid 1.7 mg

50 μg folic acid

Calcium Pantothenate 0.5mg

Mineral mixture

Ferrous Sulfate 1.75 mg

Zinc Oxide 0.82 mg

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Dibasic calcium phosphate 55 mg

Potassium Citrate 90 mg

Calcium Carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified. The granules may be prepared and used for preparing a health food composition according to a conventional method.

Formulation Example 7 Preparation of Healthy Drink

1 g of red pepper acid extract

Citric acid 1000 mg

100 g oligosaccharides

Plum concentrate 2 g

1 g of taurine

Add 900 ml of purified water

After mixing the above components according to a conventional healthy beverage production method, and then stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and refrigerated and then stored in the present invention It can be used for the manufacture of healthy beverage composition. Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.

Claims (11)

Asthma, allergic rhinitis, containing Ohjisan prescription extract consisting of creation, ephedra, dermis, hindsight, Gilkyung, crust, donkey, health, earl, baekbokyeong, white paper, cheonggung, half, cinnamon, licorice, ginger and baekbaek as active ingredients Immunity enhancement pharmaceutical composition for the prevention or treatment of diseases caused by lowered immune function selected from the group consisting of chronic fatigue and cancer.
delete The pharmaceutical composition of claim 1, wherein the formulation is extracted by extracting the ohmic acid with water, C ₁ to C ₄ alcohol, or a mixed solvent thereof.
According to claim 3, wherein the formulation of the five-acid formula extract is immune enhancing pharmaceutical composition, characterized in that prepared by extracting with methanol or ethanol.
delete Immunity enhancing food composition which contains a prescription ingredient of Ojeoksan composed of creation, ephedra, dermis, hunch, gilkyung, crust, donkey, health, earl, baekbokyeong, white paper, cheonggung, half, cinnamon, licorice, ginger and baekbaek as an active ingredient .
delete delete The method of claim 1, wherein the formulation of the five-acid acid extract extracts the five-acid acid with an extraction solvent to prepare an extract; And Immune enhancing pharmaceutical composition prepared by the step of drying the extract.
The method of claim 6, wherein the extraction solvent is immune, food composition for immune enhancement, characterized in that the C ₁ to C ₄ alcohol or a mixed solvent thereof.
The food composition for immune boosting according to claim 10, wherein the extraction solvent is ethanol or methanol.

Images